ストックスクリーナーアプリを入手
0.7834
2.53%
-0.0203
前日終値:
$0.8037
開ける：
$0.815
24時間の取引高:
2.01M
Relative Volume:
0.46
時価総額：
$230.80M
収益：
$55.87M
当期純損益:
$-77.60M
株価収益率:
-2.1962
EPS:
-0.3567
ネットキャッシュフロー:
$-79.46M
1週間 パフォーマンス:
-12.35%
1か月 パフォーマンス:
-13.04%
6か月 パフォーマンス:
-68.91%
1年 パフォーマンス:
+5.10%
1日の値動き範囲:
$0.7676
$0.815
1週間の範囲:
$0.7676
$1.00
52週間の値動き範囲:
$0.483
$3.0699
Invivyd Inc Stock (IVVD) Company Profile
Compare IVVD vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IVVD
Invivyd Inc
|
0.7834 | 230.80M | 55.87M | -77.60M | -79.46M | -0.3567 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Invivyd Inc Stock (IVVD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-22 | 開始されました | BTIG Research | Buy |
| 2025-11-25 | ダウングレード | D. Boral Capital | Buy → Hold |
| 2025-10-06 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-04-05 | アップグレード | Guggenheim | Neutral → Buy |
| 2024-03-26 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2023-12-19 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2023-05-01 | 開始されました | H.C. Wainwright | Buy |
すべてを表示
Invivyd Inc (IVVD) 最新ニュース
Analysts Conflicted on These Healthcare Names: Cipher Pharmaceuticals (OtherCPHRF), Invivyd (IVVD) and Merck & Company (MRK) - The Globe and Mail
Invivyd Inc updates investors on its antiviral pipeline as Nasdaq-listed biotech advances - ad-hoc-news.de
H.C. Wainwright reiterates Invivyd stock rating on regulatory path - Investing.com
H.C. Wainwright reiterates Invivyd stock rating on regulatory path By Investing.com - Investing.com South Africa
Invivyd Inc. (IVVD) Surges Nearly 13% as Bulls Test Key Resistance at $0.99Protective Put - dars.gov.et
Invivyd Inc stock and Covid antibody focus - Ad-hoc-news.de
IVVD Reiterated by BTIG -- Price Target Maintained at $10.00 - GuruFocus
symbol__ Stock Quote Price and Forecast - CNN
Healthcare Stocks Decline as Investors Rotate Away From Safety -- Healthcare Roundup - Moomoo
IVVD Stock Drops As PEMGARDA Loses Emergency Authorization In 2027 — Invivyd Eyes Full FDA Approval - Stocktwits
FDA to terminate PEMGARDA emergency authorization in June 2027 - Investing.com UK
Invivyd receives FDA termination notice for PEMGARDA EUA - grafa.com
IVVD Stock Tanks 19% Today – But This Analyst Believes It Has A Potential Upside Of Over 730% - Stocktwits
Invivyd gets notice of Pemgarda EUA termination - MSN
Invivyd receives 12-month notice of EUA termination for PEMGARDA, plans FDA dialogue - TradingView
Invivyd, Inc. ประกาศแจ้งเรื่องการสิ้นสุดการอนุญาตใช้งานในกรณีฉุกเฉิน (EUA) สำหรับ PEMGARDA จาก FDA ภายหลังจากการยุติการประกาศสถานการณ์ฉุกเฉินด้านโควิด-19 ของกระทรวงสาธารณสุขและบริการมนุษย์แห่งสหรัฐฯ (HHS) - Moomoo
Invivyd (NASDAQ: IVVD) faces 2027 end of PEMGARDA COVID EUA - Stock Titan
Invivyd, Inc. Announces FDA Notice of Termination for PEMGARDA EUA Following HHS COVID-19 Emergency Declaration Wind-Down - Quiver Quantitative
PEMGARDA faces 2027 EUA end as Invivyd talks next steps with FDA - Stock Titan
IVVDInvivyd Inc Short Interest - Finviz
Price to earnings forward of Invivyd, Inc. – NASDAQ:IVVD - TradingView
Price to sales forward of Invivyd, Inc. – NASDAQ:IVVD - TradingView
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - 富途牛牛
Invivyd gives 14 new hires stock options worth 493,000 shares - Stock Titan
IVVD News | INVIVYD INC (NASDAQ:IVVD) - ChartMill
New Haven biotech company developing measles treatment as US cases top 2,100 - WFSB
Invivyd, Inc.(NasdaqGM: IVVD) added to Russell 2000 Index - marketscreener.com
Invivyd, Inc.(NasdaqGM: IVVD) added to Russell Microcap Value Benchmark Index - marketscreener.com
Invivyd, Inc.(NasdaqGM: IVVD) added to Russell 2000 Value Benchmark - marketscreener.com
Invivyd, Inc.(NasdaqGM: IVVD) added to Russell Microcap Index - marketscreener.com
Invivyd, Inc.(NasdaqGM: IVVD) added to Russell 3000 Index - marketscreener.com
Invivyd, Inc.(NasdaqGM: IVVD) added to Russell 3000E Value Benchmark - marketscreener.com
Invivyd, Inc. Actuals & Estimates (NASDAQ:IVVD) - TradingView
IVVD Forecast — Price Target — Prediction for 2027 - TradingView
Invivyd Shareholder Notice - TMX Newsfile
Lobbying Update: $60,000 of INVIVYD INC. lobbying was just disclosed - Quiver Quantitative
Invivyd, Inc. (IVVD) reports Q1 loss, lags revenue estimates - MSN
Invivyd Inc (IVVD) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Invivyd Inc (IVVD) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Invivyd Inc (IVVD) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Invivyd, Inc.(NasdaqGM: IVVD) dropped from S&P Biotechnology Select Industry Index - marketscreener.com
Invivyd (IVVD) Doses First Participants in Phase 3 Trial for VYD2311 - Insider Monkey
INVIVYD INC (IVVD) Stock Chart - ChartMill
Invivyd, Inc. spotlights new data for solid organ transplant recipients in Boston - Traders Union
Invivyd Inc (IVVD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Invivyd Inc (IVVD) Valuation: PE, PB & Fair Value Analysis - TradingKey
Invivyd Inc (IVVD) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Invivyd Inc (IVVD) Institutional Confidence - TradingKey
Invivyd Inc (IVVD) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Invivyd Inc (IVVD) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Invivyd completes Phase 3 COVID-19 antibody trial enrollment - grafa.com
Invivyd Inc (IVVD) 財務データ
収益
当期純利益
現金流量
EPS
Invivyd Inc (IVVD) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Allen Robert D. III | Chief Scientific Officer |
Feb 17 '26 |
Sale |
1.54 |
18,189 |
28,004 |
133,879 |
| Green Julie | Chief Human Resources Officer |
Feb 18 '26 |
Sale |
1.58 |
20,964 |
33,077 |
107,717 |
| Green Julie | Chief Human Resources Officer |
Feb 17 '26 |
Sale |
1.54 |
19,663 |
30,273 |
128,681 |
| Duke William E. | Chief Financial Officer |
Feb 18 '26 |
Sale |
1.58 |
20,964 |
33,077 |
107,717 |
| Duke William E. | Chief Financial Officer |
Feb 17 '26 |
Sale |
1.54 |
19,663 |
30,273 |
128,681 |
| Lee Timothy Edward | Chief Commercial Officer |
Feb 18 '26 |
Sale |
1.58 |
20,964 |
33,077 |
117,717 |
| Lee Timothy Edward | Chief Commercial Officer |
Feb 17 '26 |
Sale |
1.54 |
19,663 |
30,273 |
138,681 |
| Andersen Jill | Chief Legal Officer, Secretary |
Feb 18 '26 |
Sale |
1.58 |
34,939 |
55,127 |
181,736 |
| Andersen Jill | Chief Legal Officer, Secretary |
Feb 17 '26 |
Sale |
1.54 |
32,771 |
50,454 |
216,675 |
2.64%
大文字化:
|
ボリューム (24 時間):